Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing.

Background: Rademikibart (CBP-201) is a potent, next-generation, optimized IL-4Rα-targeting antibody.

Objectives: To evaluate rademikibart efficacy and safety, initially dosed every other week (Q2W), and Q2W or every fourth week (Q4W) from Week 16, in Chinese adults/adolescents with moderate-to-severe atopic dermatitis (AD).

Methods: SEASIDE CHINA (NCT05017480) was a phase II trial: Stage 1 (16-week treatment period), Stage 2 (36-week treatment and 8-week follow-up periods).

Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial.

Rationale: Rademikibart (formerly CBP-201) is an IL-4Rα-targeting antibody.

Objectives: To evaluate rademikibart in adults with moderate-to-severe, persistent, uncontrolled asthma.

Methods: In this global phase 2b trial (NCT04773678), 322 patients were randomized 1:1:1 to two rademikibart groups (150 mg or 300 mg every other week, following a 600 mg loading dose) or placebo, administered subcutaneously, for 24 weeks.